Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to announce it has upgraded its U.S. listing to the OTCQB Venture Market (OTCQB), effective at the opening of trading today, February 3, 2021.

“Upgrading to the OTCQB is a milestone for the Company that shows our commitment to building our shareholder base,” said Robert Thast, CEO of Izotropic. “We believe the upgrade will enhance trading liquidity through increased market visibility and awareness in the U.S. investment community.”

The upgrade announcement comes one day after the World Health Organization announced that breast cancer has now surpassed lung cancer as the most common form of the disease, demonstrating the need for earlier detection and improved breast imaging technologies.


For investor relations inquiries contact:

Dan Sammartino
Phone: 1-778-962-0234
Email: IR@izocorp.com

For general inquiries contact:

Izotropic Corporation
Phone: 1-833-IZOCORP
Email: info@izocorp.com

About Izotropic Corporation

Izotropic Corporation is commercializing dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers. Extensive preliminary studies have found that breast CT may be able to routinely detect small breast tumors in the 3-5 mm size range. The median size of breast cancer found using mammography is approximately 11 mm. Routine detection of 3 mm lesions would result in 1.5 year earlier detection over mammography.

The initial indication for use for breast CT as a diagnostic device has been confirmed. Forthcoming business objectives include identifying additional indications for use, development of accessories, and additional products, all aimed at making breast CT an indispensable tool for improving the outcomes of breast cancer.

Additional information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com


Forward Looking Statements

This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such they may cause future results of the company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this document should be deemed to be medical or other advice of any kind.